Pozelimab

Pozelimab is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is a fully human antibody that targets the complement protein C5, which plays a crucial role in the activation of the complement system, a part of the immune system.

Mechanism of Action

Pozelimab works by binding to the C5 protein, inhibiting its cleavage into C5a and C5b. This inhibition prevents the formation of the membrane attack complex (MAC), which is responsible for cell lysis and inflammation in autoimmune conditions. By blocking this pathway, pozelimab reduces the inflammatory response and tissue damage associated with these diseases.

Clinical Applications

Pozelimab is being investigated for its potential use in treating several autoimmune diseases, including:

• Paroxysmal nocturnal hemoglobinuria (PNH)
• Atypical hemolytic uremic syndrome (aHUS)
• Myasthenia gravis
• Neuromyelitis optica spectrum disorder (NMOSD)

Development and Approval

Pozelimab is currently undergoing clinical trials to evaluate its safety and efficacy. The results of these trials will determine its potential approval by regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Side Effects

As with other monoclonal antibodies, pozelimab may cause side effects, including:

• Infusion reactions
• Infections
• Headache
• Nausea

Patients receiving pozelimab should be monitored for these adverse effects and managed accordingly.

Related Pages

• Monoclonal antibody
• Autoimmune disease
• Complement system
• Paroxysmal nocturnal hemoglobinuria
• Atypical hemolytic uremic syndrome
• Myasthenia gravis
• Neuromyelitis optica spectrum disorder